Zhitong Finance App News. Recently, Hong Kong stock innovative pharmaceutical company Yuanda Pharmaceuticals (00512.HK) reported positive results. Telix Pharmaceuticals Limited (ASX: TLX), the company's key strategic partner in the field of radionuclide conjugated drugs (RDC), announced the preliminary results of an overseas phase II clinical trial (iPax-Linz study) of TLX101, an innovative global RDC product for the treatment of glioblastoma (brain cancer), which confirmed the benefits for patients. This is an important development in Yuanda Pharmaceutical's global layout in the field of anti-tumor diagnosis and treatment of nuclear drugs.

Zhitongcaijing · 04/16 10:49
Zhitong Finance App News. Recently, Hong Kong stock innovative pharmaceutical company Yuanda Pharmaceuticals (00512.HK) reported positive results. Telix Pharmaceuticals Limited (ASX: TLX), the company's key strategic partner in the field of radionuclide conjugated drugs (RDC), announced the preliminary results of an overseas phase II clinical trial (iPax-Linz study) of TLX101, an innovative global RDC product for the treatment of glioblastoma (brain cancer), which confirmed the benefits for patients. This is an important development in Yuanda Pharmaceutical's global layout in the field of anti-tumor diagnosis and treatment of nuclear drugs.
Recently
Symbol
Price
%Change